Latest MDS Stories
WHITE PLAINS, N.Y., June 27, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) was deeply saddened to learn of the death of the supremely talented Nora Ephron, from acute myelogenous leukemia (AML). Ephron had been battling myelodysplastic syndrome (MDS), which then progressed to AML. MDS is a group of diseases of the blood and bone marrow, with varying degrees of severity. Sometimes MDS can develop as a result of treatment for a different cancer. MDS is often a...
ROCKVILLE, Md., June 13, 2012 /PRNewswire/ -- This week's announcement by ABC News' Robin Roberts that she has been diagnosed with MDS (myelodysplastic syndrome) has drawn national attention to this bone marrow failure disorder. Since 1983, the Aplastic Anemia & MDS International Foundation (www.AAMDS.org) has provided education and support to patients with MDS. MDS is a group of rare disorders affecting the bone marrow. People with MDS have an abnormal number of red and white...
JERUSALEM, March 24, 2010 /PRNewswire/ -- - Investment Enables Market Leading Digital Signage Solutions Provider to Broaden its Platform and Expand its Services to Meet Market Requirements Minicom Advanced Systems, a developer of remote access, KVM, and digital signage solutions, today announced that it would spinout its digital signage division ("MDS"). The new company simultaneously announced that it had raised $6 million to finance its operations independently. The...
PALO ALTO, Calif., Jan. 25 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 1 clinical study to evaluate ezatiostat hydrochloride (TELINTRA, TLK199) tablets in combination with lenalidomide (Revlimid) in patients with Myelodysplastic Syndrome (MDS). This Phase 1 trial is an open label, multicenter, dose escalation study of TELINTRA in combination with lenalidomide in patients with non-deletion (5q-) low to intermediate-1 risk MDS. TELINTRA will...
PALO ALTO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that the positive results from a Phase 1 multicenter, dose escalation study of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with Myelodysplastic Syndrome (MDS) have been published in a leading peer reviewed journal, Blood, 25 June 2009; Vol. 113, No. 26, pp. 6533-6540. Positive results from a separate Phase 1-2a study in MDS patients involving an intravenous formulation of...
WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an alternative five-day dosing regimen for Dacogen(R) (decitabine for injection) to treat patients with myelodysplastic syndromes (MDS). MDS is a potentially life-threatening group of bone marrow diseases that limit the production of functional blood cells....
Celgene Corporation (Nasdaq:CELG) today announced VIDAZA (azacitidine) received expanded U.S. Food and Drug Administration (FDA) approval to reflect new overall survival achieved in the AZA-001 survival study of patients with higher-risk myelodysplastic syndromes (MDS). This expanded indication supplements the 2004 FDA authorization of VIDAZA as the first therapy approved in the U.S. for the treatment of patients with all five French American British (FAB) subtypes of MDS. VIDAZA is also the...
GE Digital Energy announces the MDS SD4, a long range, low-power consumption and solar-friendly industrial wireless radio ideal for customers operating in rugged, remote environments such as the oil and gas, utility, water/waste water and rail industries. The much-anticipated SD4, the next generation of MDS licensed radios, sets new standards for modern wireless Supervisory Control and Data Acquisition (SCADA) networks. Its 30% longer range means that more remote points can be monitored...
WOODCLIFF LAKE, N.J., July 1, 2008 /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in 2002 comparing Dacogen(R) (decitabine) to Best Supportive Care (BSC) in elderly patients with myelodysplastic syndromes (MDS). The data did not demonstrate a statistically significant advantage of Dacogen treatment on median overall survival. However, response rates were similar to those observed in other clinical trials of Dacogen in...
DUBLIN, Calif., July 1 /PRNewswire-FirstCall/ -- SuperGen Inc. , a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today commented on the preliminary efficacy data from a trial, initiated in 2002, comparing Dacogen(R) (decitabine) for Injection to best supportive care (BSC) in elderly patients with myelodysplastic syndromes (MDS). The data did not demonstrate a statistically significant...
